Complete financial analysis of Artivion, Inc. (CRY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Artivion, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Grade Upon Technology Corp (6739.TWO) Income Statement Analysis – Financial Results
- Enel SpA (ENLAY) Income Statement Analysis – Financial Results
- Quattro Exploration and Production Ltd. (QEXXF) Income Statement Analysis – Financial Results
- Fusen Pharmaceutical Company Limited (1652.HK) Income Statement Analysis – Financial Results
- BARODA RAYON CORPORATION LTD. (BARODARY.BO) Income Statement Analysis – Financial Results
Artivion, Inc. (CRY)
About Artivion, Inc.
Artivion Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion Inc. in January 2022. Artivion Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 | 1992 | 1991 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 354.00M | 313.79M | 298.84M | 253.23M | 276.22M | 262.84M | 189.70M | 180.38M | 145.90M | 144.64M | 140.76M | 131.72M | 119.63M | 116.65M | 111.69M | 105.06M | 94.76M | 81.31M | 69.28M | 62.38M | 59.53M | 77.80M | 87.67M | 77.10M | 66.72M | 60.70M | 50.90M | 37.00M | 29.00M | 23.60M | 21.20M | 19.60M | 15.30M |
| Cost of Revenue | 124.83M | 111.27M | 101.32M | 85.44M | 93.21M | 89.86M | 61.06M | 61.48M | 55.18M | 53.35M | 50.38M | 46.70M | 43.78M | 48.28M | 41.92M | 37.27M | 35.54M | 37.42M | 32.42M | 37.63M | 31.48M | 65.63M | 36.63M | 30.13M | 27.02M | 21.80M | 15.10M | 11.20M | 9.50M | 8.00M | 8.10M | 8.80M | 7.10M |
| Gross Profit | 229.18M | 202.52M | 197.51M | 167.78M | 183.01M | 172.98M | 128.64M | 118.90M | 90.72M | 91.29M | 90.39M | 85.02M | 75.84M | 68.37M | 69.77M | 67.79M | 59.22M | 43.89M | 36.86M | 24.76M | 28.05M | 12.16M | 51.04M | 46.97M | 39.71M | 38.90M | 35.80M | 25.80M | 19.50M | 15.60M | 13.10M | 10.80M | 8.20M |
| Gross Profit Ratio | 64.74% | 64.54% | 66.09% | 66.26% | 66.26% | 65.81% | 67.81% | 65.92% | 62.18% | 63.12% | 64.21% | 64.55% | 63.40% | 58.61% | 62.47% | 64.53% | 62.49% | 53.98% | 53.20% | 39.69% | 47.12% | 15.63% | 58.22% | 60.93% | 59.51% | 64.09% | 70.33% | 69.73% | 67.24% | 66.10% | 61.79% | 55.10% | 53.59% |
| Research & Development | 28.71M | 38.88M | 35.55M | 24.21M | 22.96M | 23.10M | 19.46M | 13.45M | 10.44M | 8.70M | 8.45M | 7.26M | 6.90M | 5.92M | 5.25M | 5.31M | 4.45M | 3.55M | 3.72M | 3.94M | 3.64M | 4.60M | 4.74M | 5.21M | 4.40M | 4.70M | 3.90M | 2.80M | 2.60M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 183.50M | 155.84M | 168.77M | 140.04M | 143.01M | 140.57M | 101.21M | 91.55M | 74.93M | 73.75M | 68.11M | 65.15M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 1.90M | 1.60M | 1.00M | 1.10M | 1.70M | 732.00K | 606.00K | 384.00K | 521.00K | 821.00K | 880.00K | 4.20M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 208.98M | 157.44M | 169.77M | 141.14M | 143.01M | 140.57M | 101.21M | 91.55M | 74.93M | 73.75M | 68.11M | 65.15M | 57.30M | 49.06M | 50.03M | 48.83M | 46.47M | 41.55M | 53.23M | 42.64M | 53.63M | 47.53M | 33.84M | 28.73M | 24.69M | 23.90M | 20.50M | 15.70M | 12.80M | 13.10M | 11.70M | 9.00M | 8.20M |
| Other Expenses | 0.00 | -3.11M | -6.14M | -3.13M | -1.25M | -141.00K | 260.00K | -437.00K | -484.00K | -540.00K | 26.00K | -47.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 3.22M | 3.15M | 3.50M | 2.70M | 1.40M | 1.00M | 1.00M | 700.00K | 700.00K | 600.00K |
| Operating Expenses | 223.43M | 196.32M | 205.32M | 165.34M | 165.97M | 163.67M | 120.67M | 104.99M | 85.37M | 82.45M | 76.57M | 72.41M | 64.20M | 54.99M | 55.27M | 54.26M | 50.92M | 45.09M | 56.95M | 46.58M | 57.27M | 52.13M | 38.58M | 37.16M | 32.24M | 32.10M | 27.10M | 19.90M | 16.40M | 14.10M | 12.40M | 9.70M | 8.80M |
| Cost & Expenses | 348.26M | 307.59M | 306.64M | 250.79M | 259.18M | 253.53M | 181.73M | 166.48M | 140.54M | 135.80M | 126.94M | 119.11M | 107.98M | 103.26M | 97.19M | 91.52M | 86.46M | 82.51M | 89.37M | 84.20M | 88.76M | 117.76M | 75.21M | 67.29M | 59.26M | 53.90M | 42.20M | 31.10M | 25.90M | 22.10M | 20.50M | 18.50M | 15.90M |
| Interest Income | 1.08M | 147.00K | 79.00K | 217.00K | 738.00K | 226.00K | 212.00K | 72.00K | 107.00K | 50.00K | 4.00K | 6.00K | 14.00K | 23.00K | 76.00K | 381.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 25.30M | 18.22M | 16.89M | 16.70M | 14.89M | 15.79M | 4.88M | 3.04M | 62.00K | 175.00K | 71.00K | 179.00K | 142.00K | 180.00K | 83.00K | 263.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 23.08M | 22.44M | 23.98M | 27.86M | 23.33M | 18.10M | 9.73M | 8.38M | 5.86M | 6.03M | 5.84M | 5.63M | 4.96M | 3.94M | 4.26M | 4.35M | 4.46M | 4.84M | 5.04M | 5.48M | 5.51M | 5.42M | 4.61M | 3.22M | 3.15M | 3.50M | 2.70M | 1.40M | 1.00M | 1.00M | 700.00K | 700.00K | 600.00K |
| EBITDA | 26.87M | 19.73M | 25.04M | 20.24M | 39.98M | 30.21M | 18.18M | 25.29M | 11.22M | 14.87M | 19.66M | 17.86M | 16.57M | 11.39M | 18.70M | 18.15M | 12.76M | 3.64M | -14.58M | -16.09M | -23.72M | -34.54M | 17.07M | 13.03M | 10.62M | 10.30M | 11.40M | 7.20M | 4.10M | 2.50M | 1.40M | 1.80M | 0.00 |
| EBITDA Ratio | 7.59% | 8.18% | 3.38% | -0.19% | 5.98% | 3.58% | 4.45% | 7.51% | 3.06% | 9.94% | 9.84% | 9.54% | 9.74% | 11.49% | 16.86% | 13.13% | 14.07% | 1.90% | -21.64% | -26.17% | -39.82% | -42.25% | 20.44% | 16.69% | 19.11% | 12.69% | 22.40% | 19.19% | 13.10% | 9.75% | 6.60% | 9.18% | -1.31% |
| Operating Income | 5.74M | 3.24M | -13.86M | 2.44M | -1.79M | 9.31M | 7.97M | 21.82M | 5.35M | 8.84M | 13.82M | 12.61M | 11.64M | 9.87M | 14.50M | 13.65M | 8.30M | -1.20M | -20.09M | -21.82M | -29.22M | -39.97M | 12.46M | 9.81M | 7.46M | 6.80M | 8.70M | 5.90M | 3.10M | 1.50M | 700.00K | 1.10M | -600.00K |
| Operating Income Ratio | 1.62% | 1.03% | -4.64% | 0.96% | -0.65% | 3.54% | 4.20% | 12.10% | 3.67% | 6.11% | 9.82% | 9.58% | 9.73% | 8.46% | 12.98% | 13.00% | 8.76% | -1.48% | -29.00% | -34.98% | -49.09% | -51.37% | 14.21% | 12.73% | 11.19% | 11.20% | 17.09% | 15.95% | 10.69% | 6.36% | 3.30% | 5.61% | -3.92% |
| Total Other Income/Expenses | -27.33M | -21.19M | -22.94M | -19.62M | -15.40M | -15.70M | -4.41M | -3.41M | 514.00K | -135.00K | 9.47M | -560.00K | -177.00K | -2.59M | -142.00K | -118.00K | -730.00K | -2.69M | -1.67M | 53.00K | -2.00K | -1.47M | 1.02M | 1.82M | -962.00K | 1.90M | -800.00K | 200.00K | 200.00K | 300.00K | 200.00K | -100.00K | -200.00K |
| Income Before Tax | -21.59M | -14.98M | -14.83M | -17.17M | 1.64M | -6.39M | 3.56M | 18.41M | 5.87M | 8.70M | 23.29M | 12.05M | 11.47M | 7.28M | 14.35M | 13.54M | 7.57M | 650.00K | -19.96M | -21.77M | -29.23M | -41.43M | 13.48M | 11.63M | 6.50M | 8.70M | 7.60M | 6.10M | 3.30M | 1.80M | 900.00K | 1.00M | -800.00K |
| Income Before Tax Ratio | -6.10% | -4.78% | -4.96% | -6.78% | 0.60% | -2.43% | 1.88% | 10.21% | 4.02% | 6.02% | 16.55% | 9.15% | 9.58% | 6.24% | 12.85% | 12.88% | 7.99% | 0.80% | -28.81% | -34.89% | -49.09% | -53.26% | 15.38% | 15.09% | 9.74% | 14.33% | 14.93% | 16.49% | 11.38% | 7.63% | 4.25% | 5.10% | -5.23% |
| Income Tax Expense | 9.10M | 4.21M | 7.00K | -492.00K | -76.00K | -2.59M | -143.00K | 7.63M | 1.86M | 1.38M | 7.12M | 4.11M | 4.10M | 3.33M | 5.68M | -19.37M | 368.00K | 285.00K | -428.00K | -3.02M | 3.07M | -13.67M | 4.31M | 3.82M | 2.05M | 2.20M | 2.90M | 2.20M | 1.10M | 500.00K | 300.00K | 300.00K | -100.00K |
| Net Income | -30.69M | -19.19M | -14.83M | -16.68M | 1.72M | -3.81M | 3.70M | 10.78M | 4.01M | 7.32M | 16.17M | 7.95M | 7.37M | 3.94M | 8.68M | 32.91M | 7.20M | 365.00K | -19.54M | -18.75M | -32.29M | -27.76M | 9.17M | 7.82M | 4.45M | 6.50M | 4.70M | 3.90M | 2.20M | 1.30M | 600.00K | 700.00K | -700.00K |
| Net Income Ratio | -8.67% | -6.12% | -4.96% | -6.59% | 0.62% | -1.45% | 1.95% | 5.98% | 2.75% | 5.06% | 11.49% | 6.03% | 6.16% | 3.38% | 7.77% | 31.32% | 7.60% | 0.45% | -28.20% | -30.05% | -54.25% | -35.68% | 10.45% | 10.14% | 6.67% | 10.71% | 9.23% | 10.54% | 7.59% | 5.51% | 2.83% | 3.57% | -4.58% |
| EPS | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.11 | 0.11 | 0.33 | 0.14 | 0.26 | 0.59 | 0.29 | 0.26 | 0.14 | 0.31 | 1.15 | 0.26 | -0.02 | -0.82 | -0.81 | -1.64 | -1.43 | 0.49 | 0.42 | 0.24 | 0.36 | 0.33 | 0.27 | 0.15 | 0.09 | 0.04 | 0.07 | -0.08 |
| EPS Diluted | -0.75 | -0.48 | -0.38 | -0.44 | 0.05 | -0.10 | 0.11 | 0.32 | 0.14 | 0.25 | 0.57 | 0.28 | 0.26 | 0.14 | 0.31 | 1.13 | 0.26 | -0.02 | -0.82 | -0.81 | -1.64 | -1.43 | 0.47 | 0.41 | 0.24 | 0.35 | 0.32 | 0.27 | 0.15 | 0.09 | 0.04 | 0.07 | -0.08 |
| Weighted Avg Shares Out | 40.74M | 40.03M | 38.98M | 37.86M | 37.12M | 35.16M | 33.01M | 31.86M | 27.74M | 27.38M | 26.89M | 26.97M | 27.44M | 27.99M | 28.11M | 27.80M | 26.33M | 24.83M | 23.96M | 23.04M | 19.69M | 19.43M | 18.81M | 18.54M | 18.51M | 17.96M | 14.46M | 14.26M | 14.35M | 14.44M | 15.00M | 10.00M | 8.75M |
| Weighted Avg Shares Out (Dil) | 40.74M | 40.03M | 38.98M | 37.86M | 37.86M | 36.41M | 34.16M | 32.82M | 28.54M | 28.31M | 27.70M | 27.41M | 27.76M | 28.27M | 28.31M | 28.35M | 26.97M | 24.83M | 23.96M | 23.04M | 19.69M | 19.43M | 19.66M | 19.23M | 18.80M | 18.40M | 14.91M | 14.86M | 14.55M | 14.44M | 15.00M | 10.00M | 8.75M |
Blink and SG Blocks Enter Into Strategic Master Development and Production Agreement to Bring Solar, Off-grid, Modular EV Charging Solutions to Market
Singapore orders Wirecard to cease payment services, return customers' funds
SG Blocks Providing Modular Buildings in New Mexico
UUP: Maybe Not A 'Dead Cat Bounce' (NYSEARCA:UUP)
SGBX Stock: Why SG Blocks Is Soaring 60%
SG Blocks and Grimshaw to Bring Rapid Coronavirus Testing Centers to Los Angeles International Airport, Facilitating Safe Travel
"WAKE UP BERCY" - Feedback on the Green Finance Event
Patented Crypto Cashback App - SocialGood App Launches on iOS
COVID-19: Hemostats and Tissue Sealants Market (2020-2024)- Roadmap for Recovery| Use of Hemostats and Tissue Sealants in Surgeries to Boost the Market Growth | Technavio
Source: https://incomestatements.info
Category: Stock Reports